Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ac-PSMA-XT
- Development stage
- Unknown
- Lead developer
- Sinotau Pharmaceutical Group
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Ac-PSMA-XT (XT381) is a novel targeted alpha-particle emitting radioligand therapy (TAT) developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The therapeutic agent consists of a ligand that specifically targets the prostate-specific membrane antigen (PSMA), which is highly expressed on the surface of prostate cancer cells, labeled with the alpha-emitting radioisotope Actinium-225. Upon binding to PSMA-positive tumor cells, the Actinium-225 delivers high linear energy transfer (LET) radiation, which induces lethal double-strand DNA breaks within the cancer cells. This mechanism allows for precise tumor cell eradication with limited exposure to surrounding healthy tissues. Early clinical data from Phase I studies indicate deep PSA declines and a manageable safety profile in heavily pretreated patients.
- Other names
- [225Ac]Ac-PSMA-XT
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on Ac-PSMA-XT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ac-PSMA-XT.